Clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, Fulcrum Therapeutics (NASDAQ:FULC) announced CEO Robert J. Gould, Ph.D., former president and founding CEO has been appointed as interim CEO as Bryan Stuart departs to pursue other opportunities. The company maintains its cash runway guidance and expects its existing cash, cash equivalents, and marketable securities will be sufficient to fund its currently planned operating expenses and capital expenditure requirements into late 2024.
Interim president and CEO Ph.D. Fulcrum's Robert J. Gould commented, 'We are entering 2023 with a tremendous amount of momentum and expect it to be a productive year for our two clinical programs: FTX-6058 for SCD, and losmapimod for FSHD.
FTX-6058 is a potential best-in-class oral HbF inducer candidate that could address critical gaps in the SCD treatment landscape. We are excited by the levels of HbF induction in our initial doses and look forward to further broadening our understanding of its effect at a higher dose. Meanwhile, the Phase 3 REACH trial with losmapimod, a potential first-to-market therapy in FSHD, is expected to complete enrollment in the second half of the year.'